FAP and neoplasm: Because FAP-targeted radiopharmaceuticals are rapidly cleared via the kidneys and exhibit low uptake in normal tissues, FAP PET provides a higher tumor-to-background ratio (TBR) and reduced physiologic uptake in organs such as the brain and liver, compared to FDG PET [107].